
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. has demonstrated robust quarterly growth, with Cabometyx achieving a 20% year-over-year increase and projected revenues surpassing $2 billion by 2025, reflecting its strong performance in the renal cell carcinoma (RCC) market. The company is also likely to expand its revenue base with expected strong penetration among neuroendocrine tumor (NET) patients, highlighted by feedback from oncologists indicating Cabo's significant potential utility. Overall, Exelixis appears well-positioned for additional value creation through its existing portfolio and upcoming product opportunities, presenting a favorable outlook amidst current market conditions.
Bears say
The financial outlook for Exelixis Inc. is negatively impacted by a potential decline in market share for cabozantinib across various indications, with expected peak market shares dropping to 20% in the first-line RCC setting, 40% in the second-line RCC setting, and 10% in HCC following regulatory failures. Additionally, the company faces significant risks including potential setbacks in research and development, increased competition, lower-than-expected product sales, and the risk of generic erosion impacting the cabozantinib franchise. Concerns have also been raised regarding the tolerability profile of cabozantinib, which may deter physicians from prescribing the drug, further complicating future revenue generation.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares